Literature DB >> 1968923

The expression of a tissue-specific self-peptide is required for allo-recognition.

I J Molina1, B T Huber.   

Abstract

We have compared the functional properties of I-Ad expressed on different cell types. Specifically, we have transfected I-A alpha d and I-A beta d cDNA into a panel of T cell thymomas of various phenotypes. Excellent class II surface expression was achieved in all T cell tumors, equivalent in level to that found on the B cell lymphoma A20. Interestingly, however, two allo-I-Ad-specific Thy differed in their recognition of the transfected tumor cells: whereas the 42H11 T cell hybridoma (THy) was stimulated very efficiently by all transfectants, the RK38.2.2 Thy did not react to any of them. Both THy responded equally well to I-Ad on A20 B lymphoma cells. Purified macrophages isolated from various sources were also differentially recognized by the two THy, although there was only a quantitative difference in stimulation. Taken together, these results are best interpreted to show that the TCR of the RK38.2.2 THy is specific for I-Ad in the context of a B cell-specific determinant, possibly a self-peptide that is naturally associated with Ia. A cross-reactive molecule could be expressed by macrophages and COS-1 cells, but not by T cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968923

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  The I-Ab-restricted alloresponse of D10.G4.1 T cells is based on the recognition of an endogenous peptide.

Authors:  G Gradehandt; N Kleber; F Mattner; S Milbradt; E Rüde
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

2.  Allogeneic tumor-specific cytotoxic T lymphocytes.

Authors:  J M Redd; A C Lagarde; C A Kruse; D Bellgrau
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.

Authors:  L J D'Orsogna; D L Roelen; I I N Doxiadis; F H J Claas
Journal:  Immunogenetics       Date:  2011-12-03       Impact factor: 2.846

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.